What it's for (Indications)
- Proglumetacin, a non-steroidal anti-inflammatory drug (NSAID), is indicated for the symptomatic relief of various inflammatory and painful conditions.
- This includes chronic inflammatory rheumatic diseases such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
- It is also used for acute musculoskeletal disorders, including bursitis, tendinitis, sprains, and strains, as well as for the management of acute gouty arthritis and primary dysmenorrhea.
- The analgesic and anti-inflammatory properties of proglumetacin make it suitable for conditions where pain and inflammation are prominent features, aiming to improve patient mobility and overall quality of life.
- Its application is primarily focused on alleviating symptoms rather than curing the underlying disease processes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of proglumetacin must be individualized to achieve the lowest effective dose for the shortest possible duration, in line with treatment goals and patient response, to minimize potential adverse effects. Typically, for adult patients, the recommended starting dosage may range from 150 mg to 300 mg daily, divided into two or three doses. This can be adjusted based on the severity of the condition, patient tolerability, and clinical judgment, but should not exceed a maximum daily dose, often 300 mg, unless specifically directed by a healthcare professional. Dosing should ideally be taken with food or milk to reduce gastrointestinal irritation. Renal and hepatic impairment, as well as advanced age, may necessitate dose reduction and careful monitoring of adverse effects and therapeutic response. |
Safety & Warnings
Common Side Effects
- Proglumetacin, like other NSAIDs, can cause a range of side effects, primarily affecting the gastrointestinal system.
- Common adverse reactions include dyspepsia, nausea, vomiting, abdominal pain, diarrhea, and constipation.
- More serious gastrointestinal events, such as ulceration, bleeding, and perforation, can occur, sometimes without warning symptoms, and can be fatal.
- Central nervous system effects may include headache, dizziness, drowsiness, vertigo, and tinnitus.
- Renal adverse events can manifest as fluid retention, edema, and, in severe cases, acute kidney injury or worsening of pre-existing renal disease.
- Cardiovascular effects, such as hypertension and edema, are also possible.
- Hypersensitivity reactions (e.
- g.
- , rash, pruritus, angioedema, bronchospasm) and elevated liver enzymes are less common but significant.
- Patients should be advised to report any unusual or severe symptoms promptly for medical evaluation.
Serious Warnings
- Black Box Warning: **CARDIOVASCULAR THROMBOTIC EVENTS:** Non-steroidal anti-inflammatory drugs (NSAIDs), including proglumetacin, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Patients with known cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Proglumetacin is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. **GASTROINTESTINAL RISK:** NSAIDs, including proglumetacin, cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.
- Proglumetacin should be used with extreme caution in patients with a history of gastrointestinal disease, such as peptic ulcer or gastrointestinal bleeding, due to the increased risk of serious adverse events, including perforation.
- Patients with cardiovascular disease or risk factors for it (e.
- g.
- , hypertension, hyperlipidemia, diabetes, smoking) should be closely monitored due to the potential for increased risk of thrombotic events.
- Renal function should be assessed before and during treatment, especially in elderly patients, those with pre-existing renal impairment, or conditions leading to volume depletion.
- Hepatic function should also be monitored due to the risk of liver enzyme elevations and, rarely, severe hepatic reactions.
- Proglumetacin may cause fluid retention and edema, which can exacerbate pre-existing heart failure or hypertension.
- It should be avoided in the third trimester of pregnancy due to risks to the fetus.
- Concomitant use with other NSAIDs, anticoagulants, antiplatelet agents, selective serotonin reuptake inhibitors (SSRIs), or corticosteroids requires careful consideration and monitoring for potential drug interactions.
How it Works (Mechanism of Action)
Proglumetacin acts as a prodrug which is primarily metabolized in vivo to its active components, including indomethacin and glumetacin. The primary mechanism of action of these active metabolites, and consequently proglumetacin, involves the non-selective inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition leads to a significant reduction in the synthesis of prostaglandins, which are crucial lipid mediators involved in the pathogenesis of inflammation, pain, and fever. By decreasing prostaglandin production, proglumetacin exerts its potent anti-inflammatory, analgesic, and antipyretic effects. The inhibition of COX-1, however, is also largely responsible for many of the gastrointestinal and renal adverse effects associated with NSAIDs, as COX-1 plays a protective homeostatic role in these systems.
Commercial Brands (Alternatives)
No other brands found for this formula.